OncoSec Medical Inc. fell out of compliance with Nasdaq's $1 minimum bid price listing rule.

The Pennington, N.J.-based developer of cancer medicine has until June 19, 2019, with a possibility for extension, to regain compliance.

OncoSec Medical plans to evaluate available options to address the deficiency and regain compliance with the rule, the company said in a filing.